This change in direction may have been brought about by the Points to Consider Document of the EMEA [65] of 2001, which particularly requested studies using malignant cell lines, or malignant tissues, or animal models of malignancies to prove the safety of insulin analogues in terms of tumour growth promotion. Here, INS is linked to neoplasm.